Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

475
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
475
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

896
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
896
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.3K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.3K
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

871
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
871
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

738
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
738
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

1.0K
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatic and Cardiovascular Outcomes in Primary Biliary Cholangitis With Metabolic-Dysfunction Associated Steatotic Liver Disease.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Letter: Therapeutic Targeting of PPARs in PBC-Additional Considerations.

Alimentary pharmacology & therapeutics·2026
Same author

Fracture risk under selective and non-selective PPAR agonists in primary biliary cholangitis.

Hepatology communications·2026
Same author

Meta-Analysis: PPAR Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis.

Alimentary pharmacology & therapeutics·2026
Same author

Graft and Patient Survival After Liver Transplantation for Primary Sclerosing Cholangitis: A French National Cohort Study.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Reply to 'The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view'.

Nature reviews. Gastroenterology & hepatology·2026

Related Experiment Video

Updated: Mar 25, 2026

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction
07:44

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction

Published on: March 25, 2022

7.0K

Primary Biliary Cirrhosis Beyond Ursodeoxycholic Acid.

Christophe Corpechot1

  • 1Hepatology Department, Reference Center for Chronic Inflammatory Biliary Diseases (MIVB), French Network for Pediatric and Adult Rare Liver Diseases (FILFOIE), INSERM UMR_S938, Saint-Antoine Hospital (Assistance Publique-Hôpitaux de Paris) and Faculty of Medicine Pierre et Marie Curie, Paris 6 University, Paris, France.

Seminars in Liver Disease
|February 13, 2016
PubMed
Summary

Ursodeoxycholic acid is the primary treatment for primary biliary cirrhosis, but new therapies offer improved management. Early identification of high-risk patients is key for successful treatment strategies.

More Related Videos

Ileectomy-induced Bile Overaccumulation in Mouse Intestine
06:55

Ileectomy-induced Bile Overaccumulation in Mouse Intestine

Published on: August 21, 2017

10.1K

Related Experiment Videos

Last Updated: Mar 25, 2026

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction
07:44

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction

Published on: March 25, 2022

7.0K
Ileectomy-induced Bile Overaccumulation in Mouse Intestine
06:55

Ileectomy-induced Bile Overaccumulation in Mouse Intestine

Published on: August 21, 2017

10.1K

Area of Science:

  • Hepatology
  • Gastroenterology
  • Pharmacology

Background:

  • Ursodeoxycholic acid (UDCA) is the sole approved drug for primary biliary cirrhosis (PBC).
  • Factors contributing to poor UDCA response and new therapeutic targets are emerging.
  • Novel agents show promise in improving prognostic markers for PBC patients.

Purpose of the Study:

  • To review current knowledge on managing primary biliary cirrhosis.
  • To propose a practical approach for selecting second-line therapies.
  • To guide clinicians in optimizing treatment strategies for PBC.

Main Methods:

  • Review of current literature on PBC pharmacotherapy.
  • Analysis of emerging treatment options and their efficacy.
  • Development of a decision-making framework for treatment selection.

Main Results:

  • Several novel agents (fibrates, budesonide, obeticholic acid) can improve prognostic markers.
  • Early identification of high-risk patients is crucial for adjunctive therapy.
  • Treatment choice should consider biochemical, histological, and tolerance profiles.

Conclusions:

  • New therapeutic targets offer significant opportunities to improve PBC management.
  • A personalized approach to second-line treatment selection is recommended.
  • Further comparative trials are needed to guide optimal therapeutic choices.